Editorial Board — Medscape Oncology

Board Members

  • Kathy D. Miller, MD
    • Indiana University School of Medicine
      Indiana University Simon Cancer Center
      Indianapolis, Indiana
  • Richard M. Stone, MD
    • Harvard Medical School
      Dana-Farber Cancer Institute
      Boston, Massachusetts
  • Nicholas J. Vogelzang, MD
    • University of Nevada School of Medicine
      Comprehensive Cancer Centers of Nevada
      Las Vegas, Nevada
  • Louis M. Weiner, MD
    • Georgetown University Medical Center
      Lombardi Comprehensive Cancer Center
      Washington, DC
  • John R. Wingard, MD
    • University of Florida
      Shands Cancer Hospital at the University of Florida
      Gainesville, Florida
 

Board Member Details

Harold J. Burstein, MD, PhD
Harold J. Burstein, MD, PhD

Professor, Department of Medicine, Harvard Medical School; Institute Physician, Dana-Farber Cancer Institute, Boston, Massachusetts

Harold J. Burstein, MD, PhD, has disclosed no relevant financial relationships.

David Kerr, MD, DSc
David J. Kerr, MD

Professor, Nuffield Department of Clinical Laboratory Science, University of Oxford; Professor of Cancer Medicine, Oxford Cancer Centre, Oxford, United Kingdom

David Kerr, MD, DSc, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Celleron Therapeutics; Oxford Cancer Biomarkers; Cancer Care Commission; IQVE; ASCO
Have a 5% or greater equity interest in: Celleron Therapeutics; Oxford Cancer Biomarkers; Cancer Care Commission; IQVEA; ASCO
Received income in an amount equal to or greater than $250 from: Celleron Therapeutics; Oxford Cancer Biomarkers; IQVEA; ASCO

Mark G. Kris, MD
Mark G. Kris, MD

Professor, Department of Medicine, Weill Cornell Medical College; Attending Physician, Memorial Sloan Kettering Cancer Center, New York, NY

Mark G. Kris, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AstraZeneca; Daiichi Sankyo Company, Limited; Pfizer Inc.
Meals and travel provided by: Genentech, Inc.

Corey J. Langer, MD
Corey J. Langer, MD

Professor of Medicine, University of Pennsylvania Medical School; Director, Thoracic Oncology, Abramson Cancer Center, Philadelphia, Pennsylvania

Corey J. Langer, MD, has disclosed the following relevant financial relationships:
Received institutional grant/research support from: Pfizer; Eli Lilly; Genentech; OSI (Astellas); Merck; GlaxoSmithKline; Nektar; Advantage; Clovis; Inovio; Ariad; StemCentrx; Takeda
Served as a scientific advisor for: AbbVie; Bristol Myers Squibb; ImClone; Pfizer; Eli Lilly; AstraZeneca; Novartis; Roche/Genentech; Bayer/Onyx; Abbott; Morphotek; Biodesix; Clarient; Caris Dx; Vertex; Synta; Celgene; Boehringer-Ingelheim; Hospira; Helsinn; Clovis; Ariad (Takeda); Takai; Regeneron
Data Safety Monitoring Committee Member: Eli Lilly; Amgen; Synta; Agennix; SWOG; Peregrine; Incyte
CME: Projects in Knowledge; Physicians' Education Resource; Network of Oncology Clinicians and Researchers; Imedex; Clinical Care Options; Research to Practice; Med Learning Group; TRM Oncology; WebMD

Maurie Markman, MD
Maurie Markman, MD

Clinical Professor of Medicine, Drexel University College of Medicine; President, Medicine & Science, Cancer Treatment Centers of America, Philadelphia, Pennsylvania

Maurie Markman, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Merck, Inc.
Serve(d) as a speaker or a member of a speakers bureau for: Genentech, Inc; Clovis; Tesaro; AstraZeneca Pharmaceuticals, LP

John L. Marshall, MD
John L. Marshall, MD

Professor, Chief, Division of Hematology-Oncology, Department of Oncology, Georgetown University; Director, Ruesch Center for the Cure of Gastrointestinal Cancers, Georgetown University Hospital, Washington, DC

John L. Marshall, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Genentech, Inc.; Amgen Inc.; Bayer HealthCare Pharmaceuticals; Celgene Corporation; Taiko Pharmaceutical Co., Ltd.; Merck & Co., Inc.; Individ-med; Caris Life Sciences, Inc.
Serve(d) as a speaker or a member of a speakers bureau for: Genentech, Inc.; Amgen Inc.; Bayer HealthCare Pharmaceuticals; Celgene Corporation; Taiko Pharmaceutical Co., Ltd.; Merck & Co., Inc.

Kathy D. Miller, MD
Kathy D. Miller, MD

Professor, Department of Hematology/Oncology; Associate Director, Indiana University School of Medicine, Indianapolis, Indiana

Kathy D. Miller, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Merck & Co.

Richard M. Stone, MD
Richard M. Stone, MD

Professor of Medicine, Harvard Medical School; Director, Translational Research Division, Dana-Farber Cancer Institute, Boston, Massachusetts

Richard M. Stone, MD, has disclosed the following relevant financial relationships:
Serve(d) as a consultant for: AbbVie; Actinium; Agios; Amgen Inc.; Arog; Astellas; AstraZeneca; Celgene; Cornerstone; Jazz; Macrogenics; Novartis; Otsuka/Astex; Pfizer; Stemline
Received research funding from: Agios; Arog; Novartis
Serve(d) on the Data Safety and Monitoring Board for: Celgene; Argenx; Takeda
Serve(d) on the Steering Committee for: Celgene

Nicholas J. Vogelzang, MD
Nicholas J. Vogelzang, MD

Professor of Clinical Medicine, University of Nevada School of Medicine, University of Nevada, Las Vegas, Nevada

Serve(d) as a consultant, advisor, or a member of a Scientific Advisory Board for: Astellas; AstraZeneca; Cancer Exper Now; Carls; Clovis; Corvus; Eisai; Exelexis; GeneCentric; Genentech; Janssen; Merck
Serve(d) as a speaker or a member of a speakers bureau for: Bayer; Carls; Clovis
Clinical/phase 1/post-registration trial with: Aravive; Arrowhead; Arvinas; AstraZeneca; Bayer; Bristol-Myers Squibb; Calithera; Clovis; Corvus; Dendreon; eFFECTOR; Eisai; Endocyte; Epizyme; ESSA; Exelexis; Genentech; Immunomedics; Kangpu; Kintor Suzhou; Macrogenics; Merck; Mirati; Modra
Project with US Oncology of Real World outcomes in metastatic prostate cancer: Amgen

Louis M. Weiner, MD
Louis M. Weiner, MD

Chairman, Francis L. and Charlotte G. Gragnani Chair and Professor, Department of Oncology, Georgetown University Medical Center; Director, Lombardi Comprehensive Cancer Center; Director, MedStar Georgetown Cancer Institute, Georgetown University Medical Center, Washington, DC

Louis M. Weiner, MD, has disclosed the following relevant financial relationships:
Serve(d) on the Scientific Advisory Board for: Celldex; Jounce Therapeutics; Immunome; Klus Pharmaceuticals; Forty-Seven, Inc.
Serve(d) on the External Advisory Board for: Cytomx
Serve(d) on the Clinical Advisory Board for: Bioxcel
Serve(d) as a consultant for: Novartis
Is the co-founder of: Jounce Therapeutics
Has investment in: Targeted Diagnostic and Therapeutics, Inc.

John R. Wingard, MD
John R. Wingard, MD

Professor, Department of Medicine, University of Florida College of Medicine; Director, Bone Marrow Transplant Program, Shands Hospital at University of Florida, Gainesville, Florida

John R. Wingard, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Shire; Celgene; Ansun BioPharma; Merck; ReViral; AlloVir; Astellas Pharma; Pluristem Therapeutics; Cidara Therapeutics
Serve(d) as a speaker or a member of a spekers bureau for: United Medical (Brazil)
Received research grant from: National Institutes of Health